HK1204573A1 - Treatment of inflammatory skin disorders - Google Patents
Treatment of inflammatory skin disordersInfo
- Publication number
- HK1204573A1 HK1204573A1 HK15105193.7A HK15105193A HK1204573A1 HK 1204573 A1 HK1204573 A1 HK 1204573A1 HK 15105193 A HK15105193 A HK 15105193A HK 1204573 A1 HK1204573 A1 HK 1204573A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- skin disorders
- inflammatory skin
- inflammatory
- disorders
- Prior art date
Links
- 230000002757 inflammatory effect Effects 0.000 title 1
- 208000017520 skin disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012902874A AU2012902874A0 (en) | 2012-07-04 | Treatment of inflammatory skin disorders | |
PCT/AU2013/000729 WO2014005183A1 (en) | 2012-07-04 | 2013-07-04 | Treatment of inflammatory skin disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1204573A1 true HK1204573A1 (en) | 2015-11-27 |
Family
ID=49881162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15105193.7A HK1204573A1 (en) | 2012-07-04 | 2015-06-01 | Treatment of inflammatory skin disorders |
Country Status (13)
Country | Link |
---|---|
US (3) | US20150150954A1 (pt) |
EP (1) | EP2869833B1 (pt) |
JP (1) | JP6273272B2 (pt) |
KR (1) | KR102068010B1 (pt) |
CN (1) | CN104394883B (pt) |
AU (1) | AU2013286812B2 (pt) |
BR (1) | BR112015000051A2 (pt) |
CA (1) | CA2877745C (pt) |
ES (1) | ES2676422T3 (pt) |
HK (1) | HK1204573A1 (pt) |
IN (1) | IN2014DN11181A (pt) |
RU (1) | RU2662564C2 (pt) |
WO (1) | WO2014005183A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6273272B2 (ja) * | 2012-07-04 | 2018-01-31 | ジージー バイオテック エルエルシー | 炎症性皮膚障害の治療 |
PL3137102T3 (pl) * | 2014-04-16 | 2022-02-07 | Zz Biotech Llc | Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry |
JP6873387B2 (ja) * | 2014-04-16 | 2021-05-19 | ジージー バイオテック エルエルシー | 創傷治癒に対するapc類似体の使用 |
JP2019534266A (ja) | 2016-10-14 | 2019-11-28 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 5員ヘテロアリール環の架橋した環誘導体、その製造方法およびその医学的使用 |
US20210268062A1 (en) * | 2018-06-28 | 2021-09-02 | Novapep Pty Ltd | Inflammatory skin disorder treatment |
CN109337974B (zh) * | 2018-12-14 | 2022-01-25 | 北京蛋白质组研究中心 | 一种检测银屑病的诊断标志物的试剂及其应用 |
SG11202106836UA (en) * | 2018-12-26 | 2021-07-29 | Direct Biologics Llc | Methods and compositions for treating skin and hair disorders |
RU2704322C1 (ru) * | 2019-06-11 | 2019-10-28 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
US4959318A (en) | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
US5516650A (en) | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
EP0380508A4 (en) | 1987-05-18 | 1991-04-03 | Integrated Genetics, Inc. | Improved protein c molecules and method for making and activating same |
US5084274A (en) | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
US4981952A (en) | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
US5093117A (en) | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
US5571786A (en) | 1990-08-16 | 1996-11-05 | Immuno Aktiengesellschaft | Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation |
AT402260B (de) | 1990-08-16 | 1997-03-25 | Immuno Ag | Protein c-hältige pharmazeutische präparation |
AT397615B (de) * | 1991-05-14 | 1994-05-25 | Immuno Ag | Arzneimittel enthaltend protein c |
WO1993009807A1 (en) | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels |
MY110664A (en) | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
DE4239150A1 (de) | 1992-11-20 | 1994-05-26 | Thomae Gmbh Dr K | O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
JP3043558B2 (ja) | 1993-10-29 | 2000-05-22 | 財団法人化学及血清療法研究所 | ヒト活性化プロテインc調製物及びその製法 |
WO1995030429A1 (en) | 1994-05-04 | 1995-11-16 | Board Of Trustees Of The University Of Arkansas | Novel ophthalmologic uses of protein c |
JP4383546B2 (ja) | 1997-04-28 | 2009-12-16 | イーライ・リリー・アンド・カンパニー | 活性化プロテインcの改良プロセシング方法 |
HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
CA2398929C (en) | 2000-02-04 | 2011-05-31 | The Scripps Research Institute | Neuroprotective, antithrombotic and anti-flammatory uses of activated protein c (apc) |
US6630138B2 (en) | 2000-02-11 | 2003-10-07 | Eli Lilly And Company | Protein C derivatives |
ATE298246T1 (de) * | 2000-03-28 | 2005-07-15 | Lilly Co Eli | Aktiviertes protein c zur behandlung von pankreatitis |
MXPA03003388A (es) | 2000-10-18 | 2005-03-07 | Maxygen Aps | Moleculas de proteina c o similares a las de proteina c activadas. |
AU2002302192B2 (en) * | 2001-06-13 | 2007-08-16 | Zz Biotech Llc | Treatment and composition for wound healing |
AU2003275948A1 (en) * | 2002-11-06 | 2004-06-07 | Novo Nordisk A/S | Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides |
ES2269858T3 (es) | 2003-04-28 | 2007-04-01 | Biofrontera Bioscience Gmbh | Utilizacion de riluzol combinado con sustancias auxiliares y aditivos adecuados pra el tratamiento de enfermedades, caracterizadas una hiperproliferacion de queratinocitos, en particular neurodermitis y psoriasis. |
US9192657B2 (en) | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
WO2005007820A2 (en) | 2003-07-08 | 2005-01-27 | The Scripps Research Institute | Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
EP1841442A4 (en) * | 2005-01-07 | 2009-12-09 | Northern Sydney And Central Co | TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES |
US20070224150A1 (en) * | 2005-03-24 | 2007-09-27 | Yongji Chung | Growth factor for hair and skin treatment |
AU2006273696B2 (en) | 2005-06-24 | 2012-08-30 | Drugrecure Aps | Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract |
EP2388263A1 (en) * | 2005-08-04 | 2011-11-23 | Sirtris Pharmaceuticals, Inc. | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators |
GR1005700B (el) * | 2006-09-01 | 2007-10-22 | (40%) ����� �������� | Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα |
US20100284997A1 (en) | 2006-10-31 | 2010-11-11 | Griffin John H | Dosing regimen of activated protein c and variants having reduced anticoagulant activity |
GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
ES2316312B1 (es) | 2008-06-20 | 2010-02-08 | Ignacio Umbert Millet | Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas. |
EP2157176A1 (en) * | 2008-08-20 | 2010-02-24 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Protein C Variants |
EP2344179A1 (en) * | 2009-04-01 | 2011-07-20 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | A method of regulating proliferation and differentiation of keratinocyes |
CN101912450A (zh) * | 2010-09-01 | 2010-12-15 | 吴业刚 | 一种治疗脚气皮炎的中西药组合物及其制备方法 |
JP6273272B2 (ja) * | 2012-07-04 | 2018-01-31 | ジージー バイオテック エルエルシー | 炎症性皮膚障害の治療 |
JP6873387B2 (ja) * | 2014-04-16 | 2021-05-19 | ジージー バイオテック エルエルシー | 創傷治癒に対するapc類似体の使用 |
PL3137102T3 (pl) * | 2014-04-16 | 2022-02-07 | Zz Biotech Llc | Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry |
US20210268062A1 (en) * | 2018-06-28 | 2021-09-02 | Novapep Pty Ltd | Inflammatory skin disorder treatment |
-
2013
- 2013-07-04 JP JP2015518732A patent/JP6273272B2/ja active Active
- 2013-07-04 KR KR1020157002889A patent/KR102068010B1/ko active IP Right Grant
- 2013-07-04 EP EP13812528.1A patent/EP2869833B1/en active Active
- 2013-07-04 AU AU2013286812A patent/AU2013286812B2/en active Active
- 2013-07-04 CA CA2877745A patent/CA2877745C/en active Active
- 2013-07-04 IN IN11181DEN2014 patent/IN2014DN11181A/en unknown
- 2013-07-04 US US14/409,215 patent/US20150150954A1/en not_active Abandoned
- 2013-07-04 RU RU2015103510A patent/RU2662564C2/ru active
- 2013-07-04 ES ES13812528.1T patent/ES2676422T3/es active Active
- 2013-07-04 BR BR112015000051A patent/BR112015000051A2/pt not_active Application Discontinuation
- 2013-07-04 CN CN201380034024.2A patent/CN104394883B/zh active Active
- 2013-07-04 WO PCT/AU2013/000729 patent/WO2014005183A1/en active Application Filing
-
2015
- 2015-06-01 HK HK15105193.7A patent/HK1204573A1/xx unknown
-
2016
- 2016-11-30 US US15/365,567 patent/US20170080062A1/en not_active Abandoned
-
2020
- 2020-05-21 US US16/880,243 patent/US11617785B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2869833B1 (en) | 2018-04-04 |
BR112015000051A2 (pt) | 2017-06-27 |
EP2869833A1 (en) | 2015-05-13 |
WO2014005183A1 (en) | 2014-01-09 |
CN104394883A (zh) | 2015-03-04 |
RU2662564C2 (ru) | 2018-07-26 |
KR20150036351A (ko) | 2015-04-07 |
KR102068010B1 (ko) | 2020-01-20 |
CN104394883B (zh) | 2017-05-31 |
JP2015521632A (ja) | 2015-07-30 |
JP6273272B2 (ja) | 2018-01-31 |
RU2015103510A (ru) | 2016-08-27 |
US20150150954A1 (en) | 2015-06-04 |
US20200276281A1 (en) | 2020-09-03 |
US20170080062A1 (en) | 2017-03-23 |
CA2877745A1 (en) | 2014-01-09 |
US11617785B2 (en) | 2023-04-04 |
IN2014DN11181A (pt) | 2015-10-02 |
AU2013286812A1 (en) | 2015-01-22 |
CA2877745C (en) | 2021-11-30 |
AU2013286812B2 (en) | 2017-04-20 |
ES2676422T3 (es) | 2018-07-19 |
EP2869833A4 (en) | 2015-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1215375A1 (zh) | 阿克曼氏菌用於治療代謝病症的用途 | |
HK1207574A1 (en) | Treatment of myelosuppression | |
HUE064634T2 (hu) | Kardiovaszkuláris betegségek kezelése | |
HK1204573A1 (en) | Treatment of inflammatory skin disorders | |
GB201506561D0 (en) | Treatment of amblyopia | |
PL2919796T3 (pl) | Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych | |
GB201202773D0 (en) | Compositions for treatment of skin disorders | |
HK1211213A1 (en) | Treatment of diseases involving mucin | |
IL225896A0 (en) | Treatment of mecp-2 related disorders | |
IL235874A0 (en) | Treatment of ocular inflammatory diseases by laquinimod | |
EP2895504A4 (en) | TRPV3 AGONISTS FOR THE TREATMENT OF SKIN DISEASES | |
ZA201501038B (en) | Treatment of wax | |
EP2838508A4 (en) | Formulations and methods for the treatment of acne and inflammatory skin diseases | |
EP3046629A4 (en) | Treatment of inflammatory skin disease | |
IL223385B (en) | Treatment of inflammatory disorders | |
AU2012902874A0 (en) | Treatment of inflammatory skin disorders | |
GB201201779D0 (en) | Treatment of inflammatory disorders | |
GB201208505D0 (en) | Treatment of skin condition | |
GB201101773D0 (en) | Treatment of inflammatory disorders | |
GB201201778D0 (en) | Treatment of inflammatory respiratory disease | |
GB201204645D0 (en) | Treatment of disease | |
GB201221118D0 (en) | Methods of treatment | |
GB201216740D0 (en) | Methods of treatment | |
GB201216748D0 (en) | Methods of treatment | |
GB201206324D0 (en) | Methods of treatment |